Stockscreener 앱 받기
1.255
4.68%
0.055
전일 마감가:
$1.20
열려 있는:
$1.21
하루 거래량:
718.72K
Relative Volume:
0.15
시가총액:
$455.79M
수익:
$1.21M
순이익/손실:
$-177.12M
주가수익비율:
-1.5688
EPS:
-0.8
순현금흐름:
$-162.37M
1주 성능:
-2.62%
1개월 성능:
+71.12%
6개월 성능:
+41.91%
1년 성능:
-43.41%
1일 변동 폭
$1.21
$1.26
1주일 범위
$1.155
$1.43
52주 변동 폭
$0.2836
$2.45
렉시콘 파마슈티컬스 Stock (LXRX) Company Profile
명칭
Lexicon Pharmaceuticals Inc
전화
(281) 863-3000
주소
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
LXRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.255 | 417.65M | 1.21M | -177.12M | -162.37M | -0.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.75 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.50 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.65 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
573.20 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.94 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
렉시콘 파마슈티컬스 Stock (LXRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-05 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-06-17 | 개시 | H.C. Wainwright | Buy |
| 2024-04-30 | 개시 | Leerink Partners | Outperform |
| 2023-03-07 | 개시 | Jefferies | Hold |
| 2022-08-12 | 개시 | Piper Sandler | Overweight |
| 2021-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-01-29 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-12-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-11-18 | 업그레이드 | Gabelli & Co | Hold → Buy |
| 2019-12-11 | 다운그레이드 | Gabelli & Co | Buy → Hold |
| 2019-11-08 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-09-11 | 업그레이드 | Gabelli & Co | Hold → Buy |
| 2019-07-29 | 다운그레이드 | Stifel | Buy → Hold |
| 2019-03-25 | 업그레이드 | Gabelli & Co | Sell → Hold |
| 2018-07-31 | 재확인 | Stifel | Buy |
| 2018-02-23 | 다운그레이드 | Needham | Buy → Hold |
| 2018-02-14 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2017-03-01 | 재확인 | H.C. Wainwright | Buy |
| 2017-03-01 | 재확인 | Wedbush | Outperform |
| 2016-10-07 | 개시 | H.C. Wainwright | Buy |
| 2016-08-05 | 재확인 | Wedbush | Outperform |
| 2016-08-02 | 개시 | Citigroup | Buy |
| 2016-03-02 | 재확인 | Wedbush | Outperform |
| 2015-11-09 | 재확인 | Wedbush | Outperform |
| 2015-09-28 | 업그레이드 | Gabelli & Co | Sell → Hold |
| 2015-09-18 | 다운그레이드 | Gabelli & Co | Hold → Sell |
| 2015-08-10 | 다운그레이드 | JP Morgan | Overweight → Neutral |
모두보기
렉시콘 파마슈티컬스 주식(LXRX)의 최신 뉴스
Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025 - The Manila Times
Lexicon Pharmaceuticals Scheduled to Release Q2 2025 Financial Results and Conduct Conference Call on August 6, 2025 - Quiver Quantitative
What drives Lexicon Pharmaceuticals Inc. stock pricePowerful market insights - jammulinksnews.com
Is Lexicon Pharmaceuticals Inc. a good long term investmentUnstoppable profit momentum - jammulinksnews.com
Lexicon Pharmaceuticals Inc. Stock Analysis and ForecastOver 200% growth - jammulinksnews.com
What analysts say about Lexicon Pharmaceuticals Inc. stockTremendous gains - Autocar Professional
H.C. Wainwright Reiterates a Buy Rating on Lexicon Pharmaceuticals (LXRX) - MSN
Lexicon Pharmaceuticals: A High-Potential Biotech Play in the Diabetes Space - AInvest
10 Hot Penny Stocks to Invest in Now - Insider Monkey
Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025) - The Manila Times
Lexicon Pharmaceuticals to Present Study on Diabetic Peripheral Neuropathic Pain at ASPN 2025 Conference - Quiver Quantitative
Revolutionary Non-Opioid Drug Could Help 100M People Suffering from Diabetic Nerve Pain - Stock Titan
What makes Lexicon Pharmaceuticals Inc. stock price move sharplyTop ROI Selections - beatles.ru
Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) market cap touched US$389m last week, benefiting both private equity firms who own 48% as well as institutions - simplywall.st
Lexicon Pharmaceuticals (LXRX) Soars 16.74% on Technical Signals - AInvest
Lexicon Pharmaceuticals Defies Expectations: What Lies Ahead? - StocksToTrade
Lexicon Pharmaceuticals Granted Nasdaq Compliance Extension - The Globe and Mail
Lexicon Pharmaceuticals receives additional compliance period from Nasdaq - Investing.com
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lexicon Pharmaceuticals, Inc. To Contact The Firm - ACCESS Newswire
While institutions own 28% of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), private equity firms are its largest shareholders with 48% ownership - Yahoo Finance
HC Wainwright Reaffirms Buy Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat
Congestive Heart Failure Market to Expand Significantly by 2034, States DelveInsight Report | Mesoblast, Bayer, Novo Nordisk, Lexicon Pharmaceuticals, Merck Sharp & Dohme LLC, Corthera - Barchart.com
Lexicon Pharmaceuticals (LXRX) Receives Buy Rating from HC Wainwright & Co. | LXRX Stock News - GuruFocus
H.C. Wainwright reiterates buy rating on Lexicon Pharmaceuticals stock By Investing.com - Investing.com Canada
Breakthrough: Sotagliflozin Cuts Dangerous Low Blood Sugar Events in Type 1 Diabetes Patients - Stock Titan
Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) | LXRX Stock News - GuruFocus
Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) - TradingView
New Clinical Data Shows Lexicon's Diabetes Drug Effective Across All Kidney Function LevelsADA Conference - Stock Titan
Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 31% - simplywall.st
Novo signs $812 million weight-loss drug license deal with US biotech Deep Apple - MarketScreener
Lexicon Pharmaceuticals surges 67% following InvestingPro’s Fair Value signal By Investing.com - Investing.com
Lexicon Pharmaceuticals at Jefferies Conference: Strategic Partnerships and Pipeline Progress - Investing.com Canada
Earnings call transcript: Lexicon Pharmaceuticals Q4 2024 beats EPS forecast By Investing.com - Investing.com UK
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Shares Bought by Northern Trust Corp - Defense World
Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times
Lexicon Pharmaceuticals, Inc. (LXRX): Analysts See 285% Upside Potential - MSN
Lexicon Pharmaceuticals' Q1 2025: Unpacking Contradictions in Trial Designs, FDA Strategies, and Partnership Plans - AInvest
Lexicon (LXRX) Advances Study on Sotagliflozin for Heart Conditions | LXRX Stock News - GuruFocus
LXRXLexicon Pharmaceuticals Inc Latest Stock News & Market Updates - Stock Titan
Analysts Just Made A Noticeable Upgrade To Their Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Forecasts - simplywall.st
Earnings Update: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Just Reported And Analysts Are Boosting Their Estimates - simplywall.st
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance
Lexicon targets late 2025 Phase 3 start for pilavapadin and expands LX9851 partnership with Novo Nordisk - MSN
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2025 Earnings Call Transcript - Insider Monkey
렉시콘 파마슈티컬스 (LXRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
렉시콘 파마슈티컬스 주식 (LXRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Sullivan Diane E. | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
36,810 |
| SOBECKI CHRISTOPHER J | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
203,865 |
| BARKER SAM L | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
124,459 |
| Amouyal Philippe | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
285,174 |
| DEBBANE RAYMOND | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
1,385,689 |
3.69%
0.28%
자본화:
|
볼륨(24시간):